While NRF2 activation in astrocytes, neurons, and vasculature also contributes to reducing metabolic stress, oxidative damage, and vascular dysfunction, the microglia-specific benefits of NRF2 remain central to its therapeutic potential in AD. This evidence concerns the gene NFE2L2 and Alzheimer disease.